Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;38:1217-1221
doi: 10.1161/hy1101.099499
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by García-Tevijano, E. R.
Right arrow Articles by Avila, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by García-Tevijano, E. R.
Right arrow Articles by Avila, M. A.
Related Collections
Right arrow Peripheral vascular disease

(Hypertension. 2001;38:1217.)
© 2001 American Heart Association, Inc.


Fourth International Seminar on Cardiovascular Biology
and Medicine: Part I

Hyperhomocysteinemia in Liver Cirrhosis

Mechanisms and Role in Vascular and Hepatic Fibrosis

Elena Ruiz García-Tevijano; Carmen Berasain; José Antonio Rodríguez; Fernando José Corrales; Roberto Arias; Antonio Martín-Duce; Juan Caballería; José María Mato; Matías Antonio Avila

From the División de Hepatología y Terapia Génica, Departamento de Medicina Interna (E.R.G.-T., C.B., F.J.C., J.M.M., M.A.A.) and Departamento de Cardiología y Cirugía Cardiovascular (J.A.R., R.A.), Facultad de Medicina, Universidad de Navarra, Pamplona, Spain; Servicio de Cirugía, Hospital Príncipe de Asturias, Alcalá de Henares (A.M.-D.), Madrid, Spain; and Servicio de Hepatología, IDIABAPS, Hospital Clínic (J.C.), Barcelona, Spain.

Correspondence to Dr. Matias A Avila, División de Hepatología y Terapia Génica, Departamento de Medicina Interna, Facultad de Medicina, Universidad de Navarra, Edificio Los Castaños, C/Irunlarrea 1, 31008 Pamplona, Spain. E-mail maavila{at}unav.es

Abstract

Abstract— Numerous clinical and epidemiological studies have identified elevated homocysteine levels in plasma as a risk factor for atherosclerotic vascular disease and thromboembolism. Hyperhomocysteinemia may develop as a consequence of defects in homocysteine-metabolizing genes; nutritional conditions leading to vitamin B6, B12, or folate deficiencies; or chronic alcohol consumption. Homocysteine is an intermediate in methionine metabolism, which takes place mainly in the liver. Impaired liver function leads to altered methionine and homocysteine metabolism; however, the molecular basis for such alterations is not completely understood. In addition, the mechanisms behind homocysteine-induced cellular toxicity are not fully defined. In the present work, we have examined the expression of the main enzymes involved in methionine and homocysteine metabolism, along with the plasma levels of methionine and homocysteine, in the liver of 26 cirrhotic patients and 10 control subjects. To gain more insight into the cellular effects of elevated homocysteine levels, we have searched for changes in gene expression induced by this amino acid in cultured human vascular smooth muscle cells. We have observed a marked reduction in the expression of the main genes involved in homocysteine metabolism in liver cirrhosis. In addition, we have identified the tissue inhibitor of metalloproteinases-1 and {alpha}1(I)procollagen to be upregulated in vascular smooth muscle cells and liver stellate cells exposed to pathological concentrations of homocysteine. Taken together, our observations suggest (1) impaired liver function could be a novel determinant in the development of hyperhomocysteinemia and (2) a role for elevated homocysteine levels in the development of liver fibrosis.


Key Words: homocysteine • methionine • muscle, smooth, vascular • liver • cirrhosis • fibrosis • gene expression




This article has been cited by other articles:


Home page
J. Nutr.Home page
D. Y. Kwon, Y. S. Jung, S. J. Kim, H. K. Park, J. H. Park, and Y. C. Kim
Impaired Sulfur-Amino Acid Metabolism and Oxidative Stress in Nonalcoholic Fatty Liver Are Alleviated by Betaine Supplementation in Rats
J. Nutr., January 1, 2009; 139(1): 63 - 68.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
J. Marsillach, N. Ferre, J. Camps, F. Riu, A. Rull, and J. Joven
Moderately High Folic Acid Supplementation Exacerbates Experimentally Induced Liver Fibrosis in Rats
Experimental Biology and Medicine, January 1, 2008; 233(1): 38 - 47.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
T. M. Welzel, H. A. Katki, L. C. Sakoda, A. A. Evans, W. T. London, G. Chen, S. O'Broin, F.-M. Shen, W.-Y. Lin, and K. A. McGlynn
Blood Folate Levels and Risk of Liver Damage and Hepatocellular Carcinoma in a Prospective High-Risk Cohort
Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1279 - 1282.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
A. Bosy-Westphal, M. Ruschmeyer, N. Czech, G. Oehler, H. Hinrichsen, M. Plauth, E. Lotterer, W. Fleig, and M. J. Muller
Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation
Am. J. Clinical Nutrition, May 1, 2003; 77(5): 1269 - 1277.
[Abstract] [Full Text] [PDF]